Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells

Meehyun Ko, Sangeun Jeon, Wang Shick Ryu, Seungtaek Kim

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC50 = 0.0022 µM).

Original languageEnglish
Pages (from-to)1403-1408
Number of pages6
JournalJournal of Medical Virology
Volume93
Issue number3
DOIs
Publication statusPublished - 2021 Mar

Bibliographical note

Funding Information:
The pathogen resource (NCCP43326) for this study was provided by the National Culture Collection for Pathogens. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF‐2017M3A9G6068245 and NRF‐2020M3E9A1041756).

Publisher Copyright:
© 2020 Wiley Periodicals LLC

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells'. Together they form a unique fingerprint.

Cite this